Literature DB >> 16466094

Can Ki-67 predict recurrence of NO squamous cell carcinoma of the tongue?

Louise Davies1, Nicholas J Hardin, Barbara G Beatty.   

Abstract

OBJECTIVES: Ki-67 is a molecular marker of cellular proliferation that predicts prognosis of some head and neck tumors. Studies of Ki-67 in oropharyngeal cancer have yielded conflicting findings. This study was designed to test Ki-67 as a marker for poor prognosis in N0 tongue squamous cell carcinoma.
METHODS: We examined 29 cases in a retrospective cohort to test the hypothesis that a high rate of tumor cell proliferation (high levels of Ki-67 staining) at the invasive edge of N0 squamous cell carcinoma of the tongue correlates with increased risk of recurrence.
RESULTS: There were 14 cases of recurrence. The average age of the patients with recurrence was 58 years. The average time to recurrence was 13.1 months. A 0% to 33% uptake of Ki-67 at the tumor's leading edge was associated with a 6-times-greater risk of recurrence. The mean length of survival for the group with 0% to 33% uptake was 21 months; for the group with > 33% uptake, it was 33 months. Overall uptake of Ki-67 and histologic grade did not correlate with risk of recurrence.
CONCLUSIONS: In this sample, low rates of Ki-67 staining at the invasive edge of the tumor predicted a risk of recurrence. These results need to be confirmed before Ki-67 can be used for predicting recurrence of tongue squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466094     DOI: 10.1177/000348940611500102

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  Ber-EP4, CK1, CK7 and CK14 are useful markers for basaloid squamous carcinoma: a study of 45 cases.

Authors:  Ryan Winters; Shelly Naud; Mark F Evans; Winifred Trotman; Peter Kasznica; Abdelmonem Elhosseiny
Journal:  Head Neck Pathol       Date:  2008-10-19

2.  Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma.

Authors:  D Wangsa; M Ryott; E Avall-Lundqvist; F Petersson; G Elmberger; J Luo; T Ried; G Auer; E Munck-Wikland
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.